The State Council, China’s cabinet, has published guidelines on innovative drug pricing that a bank analyst has described as “the most significant” in a decade, as they aim to reward drug innovation and ease pricing tension for domestic and multinational pharmaceutical companies.The framework document published this month said patented innovative drugs would be supported through value-based pricing, while the prices of generic drugs would be driven down through market competition and...